PD03-11 TOLERABILITY AND ADVERSE EFFECT PROFILE OF EVEROLIMUS IN PATIENTS WITH SPORADIC ANGIOMYOLIPOMAS

Brian T. Kadow,Daniel M. Geynisman,Brian Such,Stephen Boorjian,Surena F. Matin,Edward N. Rampersaud,Daniel McClean,Barton Milestone,Elizabeth R. Plimack,Matthew Zibelman,Alexander Kutikov,Marc C. Smaldone,David J. Chen,Rosalia Viterbo,Shreyas Joshi,Richard N. Greenberg,Eric A. Ross,Lois Malizzia,Thomas McGowan,Robert G. Uzzo

PD03-11 TOLERABILITY AND ADVERSE EFFECT PROFILE OF EVEROLIMUS IN PATIENTS WITH SPORADIC ANGIOMYOLIPOMAS

2019

INTRODUCTION AND OBJECTIVES:Level 1 evidence shows that mTOR inhibition is associated with clinically significant reductions in tumor size in angiomyolipomas (AMLs) associated with Tuberous Scleros...

Keywords:

Urology
Oncology
Everolimus
Adverse effect
Internal medicine
Medicine
Tolerability
PI3K/AKT/mTOR pathway
in patient
tumor size

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations